In brief
Experts question how and if the order will produce meaningful changes, while the pharmaceutical industry raises concerns about possible consequences.
US President Donald Trump has recently issued an executive order promising to tackle the high costs of prescription drugs, a long-standing issue for Americans. He argues that US patients pay much higher prices for medications compared to their counterparts in other countries, and aims to slash these prices significantly. The executive order suggests that Americans could see price reductions of anywhere from 30% to 80%, but many analysts doubt the feasibility of such claims.The complex American healthcare system, which includes a mix of private and public insurance, is a key factor in why drug prices are so high. In contrast, countries like Canada and Australia often enjoy lower costs due to more centralized health policies that allow for better negotiation on drug prices. The US government found that prescription drugs there can be two to four times cheaper than in America.Previous administrations have tried to address this concern, but progress has remained limited, with heavy pharmaceutical lobbying often being blamed. In his announcement, Trump vowed that the US would no longer subsidize drug costs for foreign countries and placed the responsibility for high prices squarely on the hands of drug manufacturers and Congress.The order hints at further negotiations between the Department of Health and Human Services and the pharmaceutical industry, including a proposal for "Most Favored Nation" status, which would require US drug prices to match the lowest prices offered abroad. However, the specifics on how compliance would be enforced remain unclear.In response to Trump’s announcement, stock prices for major pharmaceutical companies dipped but quickly recovered, signaling that the market may not expect immediate impactful changes. Critics argue that the order could discourage drug companies from selling affordable medications in other countries, potentially backfiring on American consumers.While some in the industry claim that this move could hamper research and supply, others, including health policy experts, are not convinced as they believe funding for research could stem from other sources. Ultimately, whether Trump's order will lead to lasting reductions in drug prices remains uncertain, with industry opposition and broader implications still unfolding.
